MOTS-c vs SLU-PP-332

MOTS-c wins for predictable safety profile, established rodent and early human data, clean synergy with AAS/recomp/longevity stacks, and moderate improvements in endurance and metabolic health without harsh sides. SLU-PP-332 wins for sheer potency in driving fat loss and mitochondrial biogenesis, dramatic rodent endurance and weight-loss numbers, ease of oral dosing, and stacking with non-peptide protocols—if you can accept unknowns around human safety and cardiac impact.

Pick MOTS-c if:

• You're focused on metabolic health, insulin sensitivity, or blunting on-cycle insulin resistance
• Want a peptide with emerging human data, low risk profile, and mild but real recomp benefits
• Endurance, longevity, or general conditioning are your priority (especially if you're stacking with AAS or GLP-1s)
• Looking for a tool that won't spike heart rate, blood pressure, or CNS stress
• Prefer cycling compounds with established peptide protocols and pulsed dosing

Pick SLU-PP-332 if:

• You want maximum non-stimulant fat-loss and mitochondrial activation, and are willing to push into the experimental zone
• Rate of visible body comp change (fat loss, endurance) is your absolute priority
• Peptide injections are a dealbreaker—oral daily dosing is preferred
• You're building a stim-free or GLP-1-based fat loss stack and want potent synergy
• You're aware of, and comfortable with, the lack of human safety data and cardiac-ERRγ risks